​

Funding Round

Series B - AlloVir

Series B - AlloVir

Investment Firm

Overview

AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases.

Announced Date

May 23, 2019

Funding Type

Series B

Highlights

N/A

Location

N/A

Social

N/A

Investor Lead

Fidelity

Fidelity

Fidelity is a convertible_note and debt and early_stage_venture and late_stage_venture and post_ipo and private_equity and secondary_market and seed firm.

Participant Investors

7

Investor Name
Participant InvestorEcoR1 Capital
Participant InvestorLeerink Partners
Participant InvestorInvus
Participant InvestorGilead Sciences
Participant InvestorFidelity

Round Details and Background

AlloVir raised $120000000 on 2019-05-23 in Series B

AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases.

Company Funding History

5

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
May 23, 2019
Series B - AlloVir
8-120.0M
Jul 27, 2022
Post-IPO Equity - AlloVir
8-126.6M
Jun 21, 2023
Post-IPO Equity - AlloVir
-75.0M
Aug 18, 2017
Grant - AlloVir
1-9.0M

Recent Activity

There is no recent news or activity for this profile.